TVTXHealthcare · BiotechnologyThe 15 Wall Street analysts covering Travere Therapeutics, Inc. hold a median 12-month price target of $75 — +15.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Travere Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TVTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.0% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $68 → $78 |
| 6 Aug 2026 | Canaccord Genuity | Maintains | Buy | $62 → $70 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $61 → $75 |
| 5 Aug 2026 | Citigroup | Maintains | Buy | $70 → $85 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $60 → $68 |
| 5 Aug 2026 | Guggenheim | Maintains | Buy | $65 → $75 |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $60 → $75 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $56 → $62 |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 June 2026 | Guggenheim | Maintains | Buy | — |
| 25 June 2026 | Guggenheim | Maintains | Buy | $56 → $65 |
| 22 June 2026 | Wedbush | Maintains | Outperform | $55 → $61 |
| 22 June 2026 | Wedbush | Maintains | Outperform | — |
| 18 June 2026 | Evercore ISI Group | Maintains | Outperform | $52 → $60 |
| 18 June 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 15 June 2026 | Citigroup | Maintains | Buy | — |
| 12 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 3 June 2026 | Citigroup | Maintains | Buy | — |
| 3 June 2026 | Wedbush | Reiterates | Outperform | — |
| 2 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TVTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Travere Therapeutics, Inc. returned +264.0% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 14% of US stocks
Cheaper than 2% of US stocks
Cheaper than 1% of US stocks
Higher than 86% of US stocks
Higher than 74% of US stocks
Higher than 98% of US stocks
Higher than 49% of US stocks
Higher than 22% of US stocks
Higher than 6% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Travere Therapeutics, Inc. has a market value of $6.2B and an enterprise value of $6.3B.
Revenue in the twelve months to 30 June 2026: $591.3M. The latest quarter grew 48.2% year on year.
Net income over the same four quarters: −$43.5M, a −7.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.46.
Free cash flow in the twelve months to 30 June 2026: $15.2M.
Trailing P/E: −226.7×; forward P/E: 11.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Travere Therapeutics, Inc. employs 497 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Travere Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Three biotech stocks, including Travere Therapeutics, are highlighted for their strong stock charts after recent earnings reports. All three have outperformed 97% of stocks over the last 12 months.
Why it matters — TVTX watchers would note that the company's stock is among a select group of biotech names showing strong relative performance over the past year.
Seeking Alpha rates Travere Therapeutics as a Buy, citing a DCF-based fair value of roughly $81 per share, implying about 27% upside. The analysis highlights FILSPARI's strong commercial ramp with $141.1M in Q2 U.S. sales and a targeted $3B+ peak opportunity across IgAN and FSGS, while assuming conservative penetration, pricing, and accounting for royalty burdens, tax credits, and IP risks.
Why it matters — A TVTX watcher would care because the analysis affirms a bullish valuation thesis centered on FILSPARI's commercial performance and its potential across IgAN and FSGS.
Travere Therapeutics' CFO Chris Cline discussed the company's growth strategy at a Canaccord Genuity discussion, citing expanded use of FILSPARI in rare kidney diseases (whose FSGS launch reportedly exceeded expectations), advancement of a late-stage candidate for classical homocystinuria, and the recently in-licensed BTK inhibitor civorebrutinib to build its renal pipeline.
Why it matters — A TVTX watcher would care because the commentary highlights the breadth of the company's renal pipeline and the momentum of its key drug FILSPARI beyond its current indications.
Travere Therapeutics announced that on August 10, 2026, its Compensation Committee granted inducement restricted stock units covering an aggregate of 38,940 shares of common stock to 12 new employees, made under Nasdaq Listing Rule 5635(c)(4) and subject to the terms of its 2018 Equity Incentive Plan.
Why it matters — The grants signal the company's use of equity incentives to attract and retain newly hired employees, a routine corporate governance development relevant to shareholders tracking executive and staff compensation.
Travere Therapeutics was downgraded from Buy to Hold on Seeking Alpha following a more than 130% rally, reflecting competitive risks and valuation concerns. Despite Filspari's Q2 net sales nearly doubling year-over-year to $141M, the $3B+ peak sales outlook faces new competition in IgAN and FSGS markets, while pipeline candidates civorebrutinib and pegtibatinase remain early-stage with uncertain timelines.
Why it matters — A TVTX watcher would care because the stock's sharp run-up has prompted a downgrade amid rising competitive and valuation pressures that could temper near-term upside for the company.
The 15 Wall Street analysts covering Travere Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $62 to $90. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Travere Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Travere Therapeutics, Inc. 84 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Travere Therapeutics, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +15.0% from the last close, and Ticker Nerd's factor model ranks Travere Therapeutics, Inc. 84 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Travere Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $62 to $90 over the next 12 months.
Travere Therapeutics, Inc. returned +264.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases.
The most recent item we track (Investors Business Daily, 21 Aug 2026): "Three Biotech Stocks Stick Out With Their Stellar Charts". Three biotech stocks, including Travere Therapeutics, are highlighted for their strong stock charts after recent earnings reports. All three have outperformed 97% of stocks over the last 12 months.
Travere Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of pioneering therapies for rare diseases. The company's primary mission is to address unmet medical needs in patient populations that have few existing treatment options. Travere Therapeutics operates in the pharmaceutical sector, focusing predominantly on nephrology and hepatology. Its pipeline includes drug candidates aimed at treating complex conditions like focal segmental glomerulosclerosis (FSGS) and Alport syndrome, both of which are linked to kidney diseases. With a strong commitment to advancing scientific research and improving patient outcomes, Travere Therapeutics partners with healthcare professionals and scientists to drive innovation in niche medical areas. The company plays a significant role in the biotech industry, providing new avenues for treating challenging health issues that affect small populations. Travere's presence in the rare disease market underscores its significance as a leader in providing hope and solutions for patients who desperately need breakthrough therapeutics.
CEO Dr. Eric M. Dube Ph.D. · 497 employees · United States · https://travere.com
